Shire has unveiled plans to split its operations into two separate entities – a neuroscience division and rare diseases one, and will later decide whether they should be listed independently.
News
Axovant shares plummet on dementia drug failure
Shares in Axovant Sciences Ltd sank almost 50 percent after investors shrank back on new of the failure of lead drug intepirdine in a mid-stage study in patients with a particular kind of dementia.
Women at risk from sub-standard heart attack care
New research part funded by the British Heart Foundation has highlighted stark inequalities between the treatment of men and women with heart attack and the effect this is having on survival.
Amgen’s Xgeva cleared for multiple myeloma patients
US regulators have expanded the scope of Amgen’s Xgeva to include the prevention of skeletal-related events in patients with multiple myeloma.
Pfizer pulls plug on early stage neuroscience projects
Pfizer has announced a planned cull of all early-stage projects in neuroscience and the related loss of around 300 jobs.
Novo makes second move on Ablynx
Novo Nordisk is switching up a gear its efforts to acquire Belgian biopharma Ablynx, with a heightened offer valued at around 2.6 billion euros.
Acacia’s PONV drug under US review
US regulators have accepted for review Cambridge, UK-based Acacia Pharma’s application for post-operative nausea and vomiting (PONV) drug Baremsis.
INC Research/inVentiv Health becomes Syneos Health.
New name “communicates the value of synchronising clinical and commercial capabilities”
CCGs failing to disclose private/charity payments, finds BMJ
Clinical Commissioning Groups in England are declaring just two-thirds of payments they have received from private companies and charities, an investigation led by the British Medical Journal has revealed.
Shire’s cytomegalovirus therapy wins ‘Breakthrough’ status
An experimental drug being developed by Shire to treat cytomegalovirus (CMV) infection has been given a boost in the US with a ‘Breakthrough Therapy Designation’.
Roche’s emicizumab cleared for early access in the UK
Roche’s emicizumab in being included in the UK’s Early Access to Medicines Scheme for routine prophylaxis of bleeding episodes in patients with haemophilia A with factor VIII inhibitors.
Pfizer, Arvinas to collaborate on PROTACs
Arvinas and Pfizer have signed a research collaboration and license agreement relating to the discovery and development of protein degradation drug candidates
Are you at the top of your game?
Prove it, by entering the PharmaTimes International Clinical Researcher of the Year TODAY!
Pfizer, Sangamo to work on gene therapies for ALS, FTLD
Pfizer and Sangamo Therapeutics are linking arms to develop a potential gene therapy to treat amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD).
AZ deepens ties with Myriad on Lynparza companion test
AstraZeneca has expanded its agreement with US group Myriad Genetics to identify women with advanced ovarian cancer most likely to benefit from its medicines.
